BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

984 related articles for article (PubMed ID: 25029122)

  • 1. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
    Herawi M; Epstein JI
    Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
    Kunju LP; Mehra R; Snyder M; Shah RB
    Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.
    Amin MB; Trpkov K; Lopez-Beltran A; Grignon D;
    Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
    Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
    Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
    Gordetsky J; Epstein JI
    Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
    Ali TZ; Epstein JI
    Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer].
    Yu T; Zhu SX; Zheng S; Chen SP
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.
    Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA
    Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
    Zhou M; Shah R; Shen R; Rubin MA
    Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
    Zhao J; Epstein JI
    Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
    Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
    Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
    Shah RB; Magi-Galluzzi C; Han B; Zhou M
    Am J Surg Pathol; 2010 Apr; 34(4):470-7. PubMed ID: 20182345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry in diagnostic surgical pathology of the prostate.
    Hameed O; Humphrey PA
    Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
    Wang W; Sun X; Epstein JI
    Am J Surg Pathol; 2008 Jun; 32(6):851-7. PubMed ID: 18408595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
    Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
    Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.